Basic Information
| LncRNA/CircRNA Name | LINC00657 |
| Synonyms | NORAD, LINC00657, ASHGA5P032173 |
| Region | GRCh38_20:36045618-36050960 |
| Ensemble | ENSG00000260032 |
| Refseq | NR_027451 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic ductal adenocarcinoma |
| ICD-0-3 | C25.3 |
| Methods | RT-qPCR, Western blot |
| Sample | PDAC tissues,cell lines |
| Expression Pattern | up-regulated |
| Function Description | LINC00657 knockdown inhibited the proliferation, migration, and invasion while promoted the apoptosis of PDAC cells. In addition, LINC00657 knockdown markedly suppressed tumor growth of these cells in vivo. In terms of the mechanism, LINC00657 could directly interact with microRNA-433 (miR-433) and effectively worked as an miR-433 sponge, thus decreasing the competitive binding of miR-433 to PAK4 mRNA and ultimately increasing PAK4 expression.LINC00657 promotes PDAC progression by increasing the output of the miR-433-PAK4 regulatory loop |
| Pubmed ID | 32116086 |
| Year | 2019 |
| Title | Long noncoding RNA LINC00657 enhances the malignancy of pancreatic ductal adenocarcinoma by acting as a competing endogenous RNA on microRNA-433 to increase PAK4 expression |
External Links
| Links for LINC00657 | GenBank HGNC NONCODE |
| Links for pancreatic ductal adenocarcinoma | OMIM COSMIC |